Navigation Links
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Date:10/23/2011

ting multiple cellular pathways and processes. By coordinating the expression of multiple genes, miRNAs are responsible for guiding proper embryonic development, immunity, inflammation, as well as cellular growth and proliferation. Misregulation of miRNAs appears to play a fundamental role in many cancers and replacement of down regulated miRNAs in tumor cells results in a positive therapeutic response

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:
       
Silence Therapeutics
Thomas Christély/Max Herrmann
+49-30-9489-2800/+44-20-7491-6520
t.christely@silence-therapeutics.com
m.herrmann@silence-therapeutics.com

Singer Capital Markets
Shaun Dobson/Claes Spång
+44-20-32057500
shaun.dobson@singercm.com
claes.spang@singercm.com
                   
Mirna Therapeutics
Paul Lammers, MD
+1-512-901-0909
plammers@mirnarx.com

M:Communications (Europe)
Peter Laing / Emma Thompson
+44-20-7920-2345 / +44-20-7920-2342
healthcare@mcomgroup.com

Vida Communication (
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
2. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
3. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Silence Therapeutics Appoints New Vice President of Research
8. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
11. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... Aug. 18, 2014 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Registration Statement on Form 10 with the U.S. ... Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... , , , , ... Elbit Imaging,(NASDAQ: EMITF ) ("Elbit Imaging" "Company") announced ... - 60%, and Gamida,Cell - 28%; both on a fully diluted ... such subsidiary in a public offering on the,Tel Aviv Stock Exchange ...
... , LIVERPOOL, ... operations of Cambian healthcare Noel Tracey to lead ... Noel has more than 15 years, experience of ... private sector. In his previous role as,director of operations at ...
... DIEGO , Feb. 1 BioMed Realty Trust, Inc. (NYSE: ... fourth quarter and year ended December 31, 2009 after the ... Alan D. Gold , Chairman and Chief Executive Officer, and Kent ... call at 10:00 a.m. Pacific Time on Thursday, February ...
Cached Biology Technology:Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 2Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 3Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 4Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 5Noel Tracey to Head Up Gray Healthcare Recovery Team 2BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results 2
(Date:8/19/2014)... abstinence syndrome (NAS) secondary to in-utero opioid exposure ... than others, but the underlying reasons are not ... are turned on or off) changes have recently ... University School of Medicine (BUSM) and Boston Medical ... study to identify some of these epigenetic changes ...
(Date:8/19/2014)... college biology and other science courses are increasingly ... and now they have a new textbook to ... Sciences," published this month by Princeton Press and ... Mathematical and Biological Synthesis (NIMBioS), teaches readers about ... used to explore and explain biological phenomena. , ...
(Date:8/19/2014)... UTSA researchers has been awarded a nearly $40,000 grant ... (NCPTT), an office of the National Park Service (NPS) ... fund a one-year study of the energy efficiency and ... in hot, humid climates. , Radiant barriers are reflective ... reflect heat back, thereby reducing the amount of heat ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... WORCESTER, Mass. Cranberry sauce is not the star ... comes to health benefits, the lowly condiment takes center ... have found that compounds in cranberries are able to ... host of human illnesses (from kidney infections to gastroenteritis ...
... successful wastewater fuel cell, researchers have coaxed common bacteria ... Bruce Logan and colleagues at Penn State University had ... Now, using starter material that could theoretically be sourced ... same microbes to generate hydrogen. By tweaking their ...
... gone" Thats the mystery The Academy of Natural Sciences ... will shed light on the environmental health of the ... less than two inches longonce were abundant in the ... steady decline has prompted Pennsylvania to classify the fish ...
Cached Biology News:Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3Microbes churn out hydrogen at record rate 2Tiny fish can yield big clues to Delaware River health 2
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Request Info...
...
Biology Products: